Berkeley, CA, United States of America

Jorge Santiago-Ortiz

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2021

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Jorge Santiago-Ortiz in Gene Delivery Systems

Introduction: Jorge Santiago-Ortiz is a prominent inventor based in Berkeley, CA. He has made significant contributions to the field of gene therapy through his innovative work on adeno-associated virus (AAV) variants. His research focuses on enhancing the efficacy of gene delivery systems, which has important implications for medical treatments.

Latest Patents: Santiago-Ortiz holds a patent for "Adeno-associated virus variants and methods of use thereof." This patent describes recombinant adeno-associated virus (rAAV) virions that comprise a variant AAV capsid protein. The rAAV virions can exhibit greater infectivity of target cells, which is crucial for effective gene therapy. The patent also outlines methods for delivering gene products to target cells in individuals by administering the rAAV. Additionally, it provides techniques for generating rAAV virions with variant AAV capsid proteins derived from ancestral AAV capsid protein amino acid sequences. He has 1 patent to his name.

Career Highlights: Santiago-Ortiz is affiliated with the University of California, where he conducts his research. His work has been instrumental in advancing the understanding of AAV technology and its applications in gene therapy. His innovative approaches have the potential to improve treatment outcomes for various genetic disorders.

Collaborations: Santiago-Ortiz has collaborated with notable colleagues, including David Stephen Ojala and Oscar Westesson. These collaborations have further enriched his research and contributed to the development of new methodologies in gene delivery.

Conclusion: Jorge Santiago-Ortiz is a key figure in the field of gene therapy, with a focus on enhancing the effectiveness of adeno-associated virus variants. His contributions through patents and collaborations continue to shape the future of gene delivery systems.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…